Matthew Borer Email and Phone Number

Kinovate Life Sciences is a wholly owned subsidiary of Nitto Denko Corporation. As the Director of Business Development, I will be responsbile for growing the oligonucleotide synthesis market, providing top-tier materials to the life science therapeutic oligo markets worldwide.

With extensive experience in MedTech and Lifesciences, I was helping companies with marketing and business development.

Led cross-functional deal and diligence teams, leading negotiations, and securing strategic partnerships in alignment with BD Biosciences' strategy, resulting in double-digit growth.• Conducted thorough evaluations and feasibility assessments of potential partnership and acquisition opportunities, prioritizing options based on strategic considerations.• Led the preparation, structuring, and negotiation of diverse transaction agreements, including licensing, R&D, and commercial collaborations, ensuring mutually beneficial outcomes.• Presented senior management with well-prepared, objective recommendations on business partnerships and acquisition opportunities, facilitating an informed decision-making process.

Selected to lead the newly created Ventures group, which developed and implemented the go-to-market strategies for new growth initiatives.• Executed investment transactions, including partnerships, strategic alliances and M&A transactions valued in the $5M to $50M range.• Drove strategy development and business cases analysis for new, high potential growth areas, resulting in double digit growth and achieving market leadership in the Sleep Apnea market.

Led an 8-member team to change the payer market’s focus from utilization management to care management and successfully mitigated the impact of a challenging reimbursement environment.

Served as key point of contact with analysts/investors in global equity markets (US & Australia) • Crafted external communications to articulate corporate growth strategy to the global investor community.

Expanded addressable market of the company's products• Launched multi-faceted clinical programs and introduced screening tools to help clinicians easily identify sleep apnea patients, resulting in a 27% increase in referring physicians.